Abstract

To investigate the anti-cancer activity, including anti-proliferative, anti-inflammatory, anti-metastatic, and apoptotic effects of Geraniin on the laryngeal cancer human epidermoid carcinoma 2 Hep-2 cell line. The laryngeal cancer Hep-2 cell line was procured from an official institution under a research project. To assess the anti-proliferative properties of Geraniin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was employed. Various concentrations of Geraniin were administered to the Hep-2 cells for 24 hours, following which its anti-inflammatory, anti-metastatic, and pro-apoptotic effects were evaluated. As a result, different concentrations of Geraniin showed different anti-proliferative roles in the laryngeal cancer Hep-2 cell line. However, the effects of Geraniin on inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), transforming growth factor-beta (TGF-β), and granulocyte-macrophage colony-stimulating factor (GM-CSF), angiogenesis/metastasis biomarker vascular endothelial growth factor (VEGF), and pro-apoptotic indicators such as Caspase 3, 8 and 9 were not statistically different in half lethal concentration 50% (½LC50), LC50, and double LC50 (2LC50) concentrations than that in LC0 concentration. Geraniin has an anti-proliferative role in the laryngeal cancer Hep-2 cell line. However, anti-inflammatory, anti-metastatic, and pro-apoptotic effects of Geraniin were not statistically significant. This may be associated with the exposure duration of the cells to Geraniin. This is the first study on this research area, and further studies are needed to evaluate this topic.

Key words: Geraniin, larynx cancer, cell line, metastasis, cell proliferation